Evidence map›Paper›PMID 38723146›Full record

ArticleProtein science : a publication of the Protein Society2024

Analysis of the homodimeric structure of a D-Ala-D-Ala metallopeptidase, VanX, from vancomycin-resistant bacteria.

Tsuyoshi Konuma, Tomoyo Takai, Chieko Tsuchiya, Masayuki Nishida, Miyu Hashiba, Yudai Yamada, Haruka Shirai, Yoko Motoda, Aritaka Nagadoi, Eriko Chikaishi and 5 more

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Tsuyoshi KonumaGraduate School of Medical Life Science, Yokohama City University, Yokohama, Kanagawa, Japan.ORCID 0000-0002-4412-2849
Tomoyo TakaiInstitute for Protein Research, Osaka University, Osaka, Japan.
Chieko TsuchiyaGraduate School of Medical Life Science, Yokohama City University, Yokohama, Kanagawa, Japan.
Masayuki NishidaGraduate School of Medical Life Science, Yokohama City University, Yokohama, Kanagawa, Japan.
Miyu HashibaGraduate School of Medical Life Science, Yokohama City University, Yokohama, Kanagawa, Japan.
Yudai YamadaGraduate School of Medical Life Science, Yokohama City University, Yokohama, Kanagawa, Japan.
Haruka ShiraiGraduate School of Medical Life Science, Yokohama City University, Yokohama, Kanagawa, Japan.
Yoko MotodaGraduate School of Medical Life Science, Yokohama City University, Yokohama, Kanagawa, Japan.
Aritaka NagadoiGraduate School of Medical Life Science, Yokohama City University, Yokohama, Kanagawa, Japan.
Eriko ChikaishiInstitute for Protein Research, Osaka University, Osaka, Japan.
Ken-Ichi AkagiInstitute for Protein Research, Osaka University, Osaka, Japan.
Satoko AkashiGraduate School of Medical Life Science, Yokohama City University, Yokohama, Kanagawa, Japan.ORCID 0000-0002-8978-6358
Toshio YamazakiInstitute for Protein Research, Osaka University, Osaka, Japan.
Hideo AkutsuGraduate School of Medical Life Science, Yokohama City University, Yokohama, Kanagawa, Japan.
Takahisa IkegamiGraduate School of Medical Life Science, Yokohama City University, Yokohama, Kanagawa, Japan.ORCID 0000-0002-1429-1844

Funding

Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS) JP22ama121001j0001Grant-in-Aid for Transformative Research Areas (A) 2323H04958JSPS KAKENHI (Grant-in-Aid for Scientific Research (C) 20K06509JSPS KAKENHI (Grant-in-Aid for Scientific Research (C) 23K05667Yokohama City University
6 · The paper itself

Abstract

Bacteria that have acquired resistance to most antibiotics, particularly those causing nosocomial infections, create serious problems. Among these, the emergence of vancomycin-resistant enterococci was a tremendous shock, considering that vancomycin is the last resort for controlling methicillin-resistant Staphylococcus aureus. Therefore, there is an urgent need to develop an inhibitor of VanX, a protein involved in vancomycin resistance. Although the crystal structure of VanX has been resolved, its asymmetric unit contains six molecules aligned in a row. We have developed a structural model of VanX as a stable dimer in solution, primarily utilizing nuclear magnetic resonance (NMR) residual dipolar coupling. Despite the 46 kDa molecular mass of the dimer, the analyses, which are typically not as straightforward as those of small proteins around 10 kDa, were successfully conducted. We assigned the main chain using an amino acid-selective unlabeling method. Because we found that the zinc ion-coordinating active sites in the dimer structure were situated in the opposite direction to the dimer interface, we generated an active monomer by replacing an amino acid at the dimer interface. The monomer consists of only 202 amino acids and is expected to be used in future studies to screen and improve inhibitors using NMR.

Indexed as

Bacterial ProteinsProtein MultimerizationSerine-Type D-Ala-D-Ala CarboxypeptidaseCatalytic DomainMetalloendopeptidasesMethicillin-Resistant Staphylococcus aureusModels, MolecularNuclear Magnetic Resonance, BiomolecularVancomycin ResistanceBacterial ProteinsMetalloendopeptidasesSerine-Type D-Ala-D-Ala CarboxypeptidaseVanX dipeptidaseamino acid‐selective unlabelingantimicrobial resistancehomodimerNMRresidual dipolar coupling (RDC)transfer cross saturation (TCS)vancomycin‐resistant enterococciVanX

Identifiers

PMID38723146
PMCPMC11081423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.